Abstract
In the US, the Biologics Price Competition and Innovation Act (BPCI Act, 2009) provided the pathway to create an abbreviated licensure procedure for biologic products that are demonstrated to be biosimilar to or interchangeable with a Food and Drug Administration (FDA) licensed biologic product.
In February 2012, the FDA issued three guidelines that list the requirements for biosimilar registration.
The topics covered include scientific and quality considerations to demonstrate biosimilarity to a reference product and a guidance that clarifies the BPCI Act implementation.
The sponsor application for the biosimilar approval must contain biosimilarity information based on data derived from analytical, animal, and clinical studies. Clinical studies should include an assessment of immunogenicity, pharmacokinetics, pharmacodynamics, and address one or more indications licensed for the reference product. To demonstrate biosimilarity the applicant is allowed to use comparative animal or clinical data with a non-US-licensed product.
According to these guidelines, the FDA will consider different aspects when evaluating biosimilarity, such as product formulation, complexity, and stability which will have a risk-based approach and will depend on the degree of knowledge of the product characteristics, as well as clinical experience with the reference one. The FDA intends to use a risk-based and facts-focused approach for review of applications of biosimilars, although it faces several challenges. Once a biologic medicine has been demonstrated to be biosimilar to the reference product, an abridged development program for the biosimilar medicine can be carried out in a similar way to that established by the European Medicines Agency (EMA). In addition, FDA legislation goes a step further than the EMA, offering the possibility to adopt full interchangeability for biosimilars.
Similar content being viewed by others
References
Biologics Price Competition and Innovation Act (2009) [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf [Accessed 2012 May 31]
See section 505(b)(2) and 505(j) of the FD&C Act (21 U.S.C. 355(b)(2) and 355(j)) [online]. Available from URL: http://www.fda.gov [Accessed 2012 May 31]
Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products. CHMP/437/04 [online]. Available from URL: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf [Accessed 2012 April 27]
Zuñiga L, Calvo B. Regulatory aspects of biosimilars in Europe. Trends Biotechnol 2009; 27: 385–7
Committee for Medicinal Products for Human Use (CHMP). Concept paper on the revision of the guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. EMA/CHMP/BWP/617111/2010 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/02/WC500102285.pdf [Accessed 2012 May 31]
Committee for Medicinal Products for Human Use (CHMP). Concept paper on the revision of the guideline on similar biological medicinal products containing biotechnology derived proteins as active substance: non-clinical and clinical issues. EMA/CHMP/BMWP/572828/2011 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/10/WC500115611.pdf [Accessed 2012 May 31]
Committee for Medicinal Products for Human Use (CHMP). Concept paper on the revision of the guideline on similar biological medicinal product. EMA/CHMP/BMWP/572643/2011[online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/11/WC500117987.pdf [Accessed 2012 May 31]
Committee for Medicinal Products for Human Use (CHMP). Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing somatropin. EMEA/CHMP/BMWP/94528/2005 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003956.pdf [Accessed 2012 May 31]
Committee for Medicinal Products for Human Use (CHMP). Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on biosimilar medicinal products containing recombinant granulocyte-colony stimulating factor. EMEA/CHMP/BMWP/31329/2005 [online]. Available from URL:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003955.pdf [Accessed 2012 May 31]
Committee for Medicinal Products for Human Use (CHMP). Non-clinical and clinical development of similar medicinal products containing recombinant interferon alpha. EMEA/CHMP/BMWP/102046/2006 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003930.pdf [Accessed 2012 May 31]
Committee for Medicinal Products for Human Use (CHMP). Similar biological medicinal products containing recombinant erythropoietins. EMEA/CHMP/BMWP/301636/08 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/04/WC500089474.pdf [Accessed 2012 May 31]
Committee for Medicinal Products for Human Use (CHMP). Revision of the guideline on nonclinical and clinical development of similar biological medicinal products containing recombinant human insulin. EMA/CHMP/BMWP/506470/2011 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/07/WC500109587.pdf [Accessed 2012 May 31]
Committee for Medicinal Products for Human Use (CHMP). Revision of the guideline on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight heparins. EMA/CHMP/BMWP/522386/2011 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/07/WC500109588.pdf [Accessed 2012 May 31]
Committee for Medicinal Products for Human Use (CHMP). Similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues. EMA/CHMP/BMWP/403543/2010 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf [Accessed 2012 May 31]
Committee for Medicinal Products for Human Use (CHMP). Similar biological medicinal products containing recombinant follicle stimulation hormone. CHMP/BMWP/671292/2010 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/11/WC500117986.pdf [Accessed 2012 May 31]
Committee for Medicinal Products for Human Use (CHMP). Similar biological medicinal product containing interferon beta. CHMP/BMWP/652000/2010 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/01/WC500120652.pdf [Accessed 2012 May 31]
Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product, February 2012 [online]. Available from URL: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm [Accessed 2012 May 31]
Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product, February 2012 [online]. Available from URL: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm [Accessed 2012 May 31]
Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009 [online]. Available from URL: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm [Accessed 2012 May 31]
Ledford H. Biotechs go generic: the same but different. Nature 2007; 449: 274–6
Gatyas G. Gobal biologics spending (2010) [online]. Available from URL: https://www.brainshark.com/imshealth/vu?pi=zGBzFL1RkzyjTz00 [Accessed 2012 May 31]
Zuniga L, Calvo B. Biosimilars: pharmacovigilance and risk management. Pharmacoepidemiol Drug Saf 2010; 19: 661–9
Kozlowski S, Woodcock J, Midthun K, et al. Developing the nation’s biosimilars program. N Engl J Med 2011; 365: 385–8
Acknowledgements
No sources of funding were used to prepare this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Calvo, B., Zuñiga, L. The US Approach to Biosimilars. BioDrugs 26, 357–361 (2012). https://doi.org/10.1007/BF03261893
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03261893